Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Medy Tox Inc    086900   KR7086900008

MEDY TOX INC (086900)
My previous session
Most popular
  Report  
No quotes available
-- KRW   --.--%
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Medy Tox : Medytox in final stage to sell facial filler in China

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/15/2018 | 01:16am EST

Medytox entry into the Chinese anti-wrinkle injections market with its self-developed botulinum toxin is drawing attention.

The Korean botox maker recently said it has completed seeking regulatory approval of the China Food and Drug Administration for Medytoxin, under the brand name of Neuronox.

Medytox finished phase-3 clinical trials for the dermal filler in China in June 2017, which was the first among Korean drugmakers.

Experts said setting the right price for Medytoxin will decide whether Medytox will be successful in China.

According to an analysis by Korea Investment & Securities, Allergans Botox, the leading botulinum toxin, sells at around 500,000 won ($460) to 700,000 won in China, much more expensive than 350,000 won to 450,000 won in the U.S.

Another botulinum toxin BTX-A by Lanzhou, a Chinese pharmaceutical firm securing the dermal filler market as much as Allergan, sells at between 350,000 won and 510,000 won.

Latecomer Medytox might give a meaningful impact on the Chinese botulinum toxin market if it sets the price of Medytoxin low, along with similar efficacy, analysts said.

Medytoxin sells at around 100,000 won per shot in Korea amid a severe price competition among botox makers.

Except for Lanzhou and Allergan, rival companies are slower than Medytox to prepare for a Chinese market entry, which gives a competitive edge to Medytox.

As Daewoong Pharmaceuticals Nabota and Hugels Botulax are in phase-3 clinical trials in China now, their market releases are expected to be around 2022-2024, observers said.

In contrast, Medytox may sell its product in 2019, as it usually takes one year from requesting for regulatory approval to receiving sales approval in China.

Medytox hopes to create a synergy with its Chinese partner firm.

Medybloom, a 50-50 joint venture between Medytox and Bloomage BioTechnology, is seeking the Chinese regulatory approval now.

Bloomage is an injectable filler giant, taking up 60 percent of the Chinese botox market and 20 percent of the global market with its hyaluronic acid (HA)-based fillers.

However, Bloomage does not have any botulinum toxin, making it highly likely that the company might try to grow Medytoxin as a flagship product through the joint venture.

Having a strong presence in China, Bloomage is a perfect partner for Medytox. If Bloomage sells Medytoxin, along with HA fillers, it will earn a great synergy effect, said Jin Heung-guk, an analyst at Korea Investment & Securities.

Medytox said China has high growth potential for cosmetics and plastic surgery markets, which are growing 20-30 percent a year.

As we set up a joint venture with a leading firm Bloomage BioTechnology in the cosmetics and plastic surgery market, we will benefit from the first-mover advantage through a distinguished marketing strategy, a Medytox official said.

(c) International 2006-2018, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDY TOX INC
2018MEDY TOX : US phase 3 studies imminent for Medytoxs liquid BTX
AQ
2018MEDY TOX : Medytox in final stage to sell facial filler in China
AQ
2018MEDY TOX : Medytox pipeline in China worth W1tr
AQ
More news
Financials (KRW)
Sales 2018 219 B
EBIT 2018 95,7 B
Net income 2018 77,2 B
Debt 2018 34,2 B
Yield 2018 0,39%
P/E ratio 2018 43,88
P/E ratio 2019 35,95
EV / Sales 2018 16,0x
EV / Sales 2019 13,6x
Capitalization 3 456 B
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 700 765  KRW
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Hyun-Ho Jeong Chief Executive Officer & Director
Gi-Hyuk Yang Director & Head-Research
Tae-Cheon Jeong Outside Director
Seung-Beom Park Director & Head-Production
Young-Ik Cheon Auditor
Sector and Competitors
1st jan.Capitalization (M$)
MEDY TOX INC3 073
JOHNSON & JOHNSON1.27%350 508
PFIZER-2.57%246 674
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291